You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Support Groups Articles
Popular Support Groups Articles
Highly Recommended Support Groups Articles
Send a link to this page to your friends and colleagues.
Fourteen entities have joined forces to form Type 1 Diabetes TrialNet, a collaborative effort to test new approaches to understanding, preventing and treating type 1 diabetes. Recruitment for the first trials is expected to begin in early 2003.
Prevention trials will attempt to stop or delay the destruction of insulin-producing beta cells in people at risk for type 1 diabetes. Treatment trials will try to preserve remaining beta cells in those with new-onset type 1 diabetes.
"TrialNet will expedite the application of discoveries in basic research to therapies that benefit people with type 1 diabetes and those at risk," says Jay Skyler, MD, of the University of Miami.
Skyler, who is the study chair for TrialNet, oversaw the Diabetes Prevention Trial Type 1 (DPT-1). DPT-1 had two components: a low-dose insulin injection trial that ended in 2001 after discovering that the injections failed to prevent type 1 diabetes; and an oral insulin trial, which will become part of the new TrialNet.
"Mounting individual trials for prevention of type 1 diabetes is a challenging, costly endeavor," says Allen Spiegel, MD, director of the National Institute of Diabetes and Digestive and Kidney Diseases, which leads the initiative. "This network provides a stable, efficient, cost-effective system for identifying people at risk for type 1 diabetes and testing the ability of promising new agents to prevent the disease."
For more information about TrialNet, call (800) 425-8361.
0 comments - Feb 1, 2003
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.